CollPlant Expands rhCollagen Partnership for Clinical & Commercial Growth
• CollPlant Biotechnologies (NASDAQ: CLGN) is a regenerative and aesthetics medicine company developing plant-derived, Type I recombinant human collagen (rhCollagen).
• The company announced an expanded agreement with STEMCELL Technologies, a biotechnology firm specializing in cell culture media, tools, and services for stem cell research and regenerative medicine.
• The amended agreement extends the use of CollPlant’s rhCollagen beyond research applications to clinical development and commercial-scale manufacturing.
• Yehiel Tal, CEO of CollPlant, emphasized that the expansion reflects market evolution and the strength of their technology.
• The partnership aligns with industry priorities on safety, consistency, and ethical sourcing, offering an alternative to animal-derived materials.
• STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services.
• STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.
• CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics.
• The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology.
• These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
• In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com.
• This press release includes forward-looking statements.
• Forward-looking statements include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future.
• These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance and are subject to risks.
Multiple factors may cause actual results to differ significantly from expectations, including:
• The company's history of losses and need for additional capital.
• Uncertainties in fundraising methods and preference for non-dilutive financing.
• Costs and timing of pre-clinical and clinical trials for breast implants and medical aesthetics.
• The ability to conduct large-animal studies on breast implants in a timely manner.
• Regulatory hurdles for rhCollagen-based products, including approval and labeling scope.
• Market acceptance of rhCollagen-based products in 3D bioprinting and medical aesthetics.
• The ability to build sales & marketing capabilities or rely on third-party distributors.
• Strategic partnerships, including the agreement with AbbVie and related financial returns.
• Intellectual property protection and risks related to infringement.
• Economic and market conditions, including financial instability and liquidity risks.
• Impact of competition and emerging technologies.
• Political and economic uncertainties, including effects of the war in Israel.
More details on risk factors are outlined in CollPlant’s most recent SEC filings.
Statements reflect current views as of the press release date, with no obligation for updates.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!